Tetra Radar · Company Timeline
Ultragenyx Pharmaceutical Inc (RARE)
Sector: Health Care
Earlier observations
- · FDA approval. The FDA approved Fayuvi for the treatment of neurologic manifestations of mucopolysaccharidosis type IIIA (MPS IIIA, Sanfilippo Syndrome type A) in pediatric patients with preserved neurodevelopmental function.
- · FDA approval. The FDA approved GENGLYCOS to reduce daily cornstarch intake as an adjunct to nutritional management in adult and pediatric patients 8 years of age and older with glycogen storage disease type Ia (GSDIa).
Observations from the last 30 days, with Clusters and Heat Signatures, are in the Tetra Radar Library.
Dates are event dates. Tetra Radar observes public information for research purposes. It does not provide investment advice.